Open Access Green as soon as Postprint is submitted to ZB.
Semin. Cancer Biol. 17, 330-343 (2007)
The clear evidence that tumor-infiltrating lymphocytes with anti-tumor activity exist in situ raises the question why renal cell carcinomas (RCCs) progress in vivo. A complex array of factors and pathways has been identified that impinges on innate and adaptive effector cells thereby inhibiting their activity against RCCs. The current picture of suppressive mechanisms that contribute to the failure of the immune system to control RCCs is reviewed here. Understanding these complex host-tumor interactions has broad implications for successful application of cytokine therapy and other forms of immunotherapy for RCC.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
7.378
2.108
33
34
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Renal cell carcinoma; Immune suppression; Tumor escape; Cytokine therapies; Immune therapies
Language
english
Publication Year
2007
HGF-reported in Year
2007
ISSN (print) / ISBN
1044-579X
e-ISSN
1096-3650
Journal
Seminars in Cancer Biology
Quellenangaben
Volume: 17,
Issue: 4,
Pages: 330-343
Publisher
Saunders
Publishing Place
Philadelphia, Pa.
Reviewing status
Peer reviewed
Institute(s)
Institute of Molecular Immunology (IMI)
POF-Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501700-001
WOS ID
000249375000008
Scopus ID
34547653931
PubMed ID
17656104
Erfassungsdatum
2007-06-23